Plant Name: Uncaria rhynchophylla
Taxonomic Information:
Plant ID: NPO14112
Plant Latin Name: Uncaria rhynchophylla
Taxonomy Genus: Uncaria
Taxonomy Family: Rubiaceae
Plant External Links:
NCBI TaxonomyDB:
43575
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCM; KampoMedicinal Functions:
Antidiarrhoeal; Antiemetic; Antispasmodic; Carminative; Febrifuge; Hepatic
Geographical Distribution:
China
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ADRA2C; ADRA2A; ADRA2B; DRD1; DRD2; | |
| ALPL; RECQL; HSD17B10; | |
| ACHE; | |
| CA12; CA9; CA7; CA3; CA14; CA5B; CA5A; CA4; CA6; | |
| RORC; | |
| NR1H4; | |
| MMP1; MMP2; MMP9; | |
| TP53; NFKB1; | |
| MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP1A2; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.136E-12 | 4.125E-09 | CA12, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, MMP1, MMP2, MMP9, NR1H4, RORC, TP53 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 2.728E-09 | 4.243E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.090E-08 | 1.187E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.090E-08 | 1.187E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 1.684E-08 | 1.746E-05 | ADRA2A, ADRA2B, ADRA2C, DRD2 |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 1.520E-07 | 1.034E-04 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.520E-07 | 1.034E-04 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 6.166E-06 | 2.500E-03 | ALPL, CA9, CYP1A2, DRD1, DRD2, NFKB1, RORC, TP53 |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 1.584E-05 | 5.148E-03 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 1.812E-05 | 5.801E-03 | DRD1, MMP2, NFKB1, NR1H4, TP53, TSHR |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 2.000E-05 | 6.198E-03 | ALPL, CA3, DRD1, DRD2, NFKB1, TP53 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 2.021E-05 | 6.198E-03 | DRD1, DRD2 |
| BP | GO:0065007; biological regulation | GO:0045761; regulation of adenylate cyclase activity | 3.716E-05 | 9.402E-03 | ADRA2A, DRD2, TSHR |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.340E-23 | 7.272E-19 | CA12, CA14, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.610E-18 | 5.019E-14 | CA12, CA14, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.910E-16 | 1.040E-12 | CA12, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.184E-22 | 1.231E-20 | CA12, CA3, CA5B, CA5A, CA4, CA7, CA6, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 3.003E-07 | 1.561E-05 | MMP1, MMP2, MMP9, TP53 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.950E-06 | 6.759E-05 | DRD1, ADRA2C, DRD2, ADRA2B, ADRA2A, TSHR |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 4.336E-05 | 1.127E-03 | DRD1, DRD2, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.027E-04 | 3.513E-03 | MMP1, MMP2, TP53, MMP9, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.615E-04 | 3.359E-03 | DRD1, DRD2, NFKB1, TSHR |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP9; TP53; MMP2; CA9; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; DRD2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C; |
| NA: NA | False perceptions | NA | DRD2; |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| NA: NA | Vomiting | NA | DRD2; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2; CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; ADRA2C; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; ADRA2A; ADRA2C; DRD1; DRD2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; DRD1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C; DRD1; DRD2; |
| NA: NA | Hyperaemia | NA | DRD2; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; DRD1; DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; ADRA2C; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADRA2C; DRD2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; DRD2; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1; |
| NA: NA | Itching | NA | DRD2; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; ACHE; MMP9; TP53; MMP2; CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; DRD2; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ADRA2C; DRD2; MAPT; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; DRD1; MAPT; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
